Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
Fennec Pharmaceuticals (NASDAQ: FENC) will release full year and fourth quarter 2025 financial results before U.S. markets open on March 24, 2026.
Rhea-AI Summary
Fennec Pharmaceuticals (NASDAQ: FENC) will release full year and fourth quarter 2025 financial results before U.S. markets open on March 24, 2026.
Management will host an 8:30 a.m. ET conference call and webcast the same day; a replay will be archived on the company website for 30 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – FENC
In the Mar 18 session, FENC declined 3.74%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Results date
- March 24, 2026
- Full year and Q4 2025 financial release
- Call time
- 8:30 a.m. Eastern Time
- Scheduled conference call on March 24, 2026
- Replay duration
- 30 days
- Webcast replay available on company website
- Current price
- $7.76
- Price before earnings date announcement
- 52-week high
- $9.92
- Pre-news 52-week range high
- 52-week low
- $4.68
- Pre-news 52-week range low
- Market cap
- $266,397,269
- Pre-news market capitalization
- 20-day avg volume
- 135,870 shares
- Compared to today’s 174,649 shares
Historical Context
-
Settlement with Cipla limiting generic PEDMARK entry until September 1, 2033.
-
Real-world PEDMARK study with Tampa General Hospital Cancer Institute.
-
Real-world PEDMARK data in adult head & neck cancer patients.
-
Southpoint sold 1,000,000 shares, cutting its stake to about 8%.
-
City of Hope Phase I trial of PEDMARK in metastatic testicular tumors.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
| Conference Call & Webcast Detail: | ||
| Date: | Tuesday, March 24, 2026 | |
| Time: | 8:30 a.m. Eastern Time | |
| Webcast Link: | https://edge.media-server.com/mmc/p/3crq898e | |
| Participant Link: | https://register-conf.media-server.com/register/BIb7d9f04377fd4b9cb7b005d167555402 | |
To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany.
PEDMARK has received Orphan Drug Exclusivity in the U.S. and.; PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.
For more information, please visit www.fennecpharma.com and follow on LinkedIn.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.